share_log

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Maintains $80 Price Target

Benzinga ·  Nov 20 06:33  · Ratings

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $80 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment